Tirzepatide Dosagem: 0.5mg 3x/Week Protocol (2026)

Split dosing cuts GI side effects vs once-weekly — here's the math. Covers 0.5mg 3x/week, titration, and reconstitution.

Tirzepatide is a dual GLP-1/GIP receptor agonist. Phase 3 trials (Frias et al., 2021; Jastreboff et al., 2022) documented superior weight loss and glycemic control compared to single-target GLP-1 agonists, with up to 22.5% body weight reduction at 72 weeks in the SURMOUNT-1 trial.

Research-context information only. Tirzepatide is the active ingredient in FDA-approved products for type 2 diabetes and chronic weight management; research-peptide and compounded forms are not FDA-approved and are sold for research purposes only. Protocols, doses, and reactions reported below come from clinical trials and community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.

FDA-approved for diabetes and weight management. Research peptide protocols use lower doses than pharmaceutical formulations. This is not medical advice.

Tirzepatide Dosing Table

Match your vial size below — reconstitution and dose math update automatically.

Math assumes U-100 insulin syringes (1 mL = 100 units). Verify your syringe matches before injecting. Round half-units to the nearest visible mark.

Math assumes U-100 insulin syringes (1 mL = 100 units). Verify your syringe matches before injecting. Round half-units to the nearest visible mark.

Math assumes U-100 insulin syringes (1 mL = 100 units). Verify your syringe matches before injecting. Round half-units to the nearest visible mark.

Running Tirzepatide ? Share your protocol

Anonymous · about 20 seconds · see how yours compares

Quick Reference: Standard Protocol

Self-reported starting doses begin around 0.25 mg 3x weekly for 2-4 weeks to assess tolerance, before increasing to 0.5 mg 3x weekly. Split dosing is described as producing more stable levels than once-weekly injection. For the full tirzepatide profile, vendor pricing, and stacking options, see our tirzepatide peptide page .

Cycling Details

The standard community cycle is 8 weeks on, 8 weeks off. Community sources describe starting conservatively at 0.25 mg 3x weekly (0.75 mg total weekly) for the first 2-4 weeks — the dual GLP-1/GIP mechanism can cause more intense initial GI side effects than single-target agonists.

Community protocols then increase to 0.5 mg 3x weekly (1.5 mg total weekly) when well-tolerated. The split-dosing approach (3x weekly vs once weekly) is described as maintaining more consistent hormone levels and reducing peak-related side effects. Some users self-report continuing until goal weight, then cycling off.

Enhanced Protocol (FDA/Clinical)

Note: The standard protocol above uses research peptide community doses. The FDA-approved protocol below uses significantly higher doses.

Community research peptide protocols use 1.5 mg/week total — roughly 60% of the FDA starting dose and 10% of the maximum. Lower doses still provide meaningful effects with substantially fewer side effects.

Routes of Administration

Subcutaneous (standard and only route): Protocols describe rotating between abdomen, thigh, and upper arm, with abdomen typically providing the most consistent absorption. Community sources describe a 29-31 gauge insulin syringe and the same time each dosing day, morning on an empty stomach preferred.

Reconstitution Quick Reference

Community-documented dilution ratios — full unit conversion math below.

10 mg vial + 2 mL BAC water = 5,000 mcg/mL. A 0.5 mg dose is 10 units on an insulin syringe.

Protocols describe swirling gently, not shaking. Storage is documented as refrigerated at 2–8°C, with use within 28 days.

Ready to buy? Compare verified vendors on our best tirzepatide sources page, or browse all coupon codes for up to 50% off.

EZ Peptides — 60 mg × 10 ( 600 mg) — $888 $799 with code thepeptidecatalog (10% off) ( $1.33 /mg)

Where These Numbers Come From

Community protocols use significantly lower doses than FDA-approved protocols, with good rationale.

SURMOUNT-1 Trial ( Jastreboff et al., 2022 ): Even at the 2.5 mg starting dose, participants achieved 16% weight loss. The dual GLP-1/GIP mechanism creates potent metabolic effects at lower doses than single-target agonists.

Head-to-Head vs Semaglutide ( Frias et al., 2021 ): Tirzepatide demonstrated superior glycemic control compared to semaglutide, supporting the dual-agonist advantage.

Research Peptide Variability: Purity and potency vary between suppliers. Starting conservatively accounts for this uncertainty. Individual sensitivity varies — some achieve excellent results well below maximum titration.

Stacking Protocols

Tirzepatide + AOD-9604

Tirzepatide + BPC-157

Stacking with other GLP-1 agonists (semaglutide, liraglutide) is described as redundant — overlapping mechanisms create added side-effect risk without proportional benefit.

Side Effects & Safety

• Nausea — up to 56% at higher FDA doses; much lower at community doses
• Vomiting — up to 36% at high doses
• Diarrhea — 23-26%
• Constipation — 17-19%
• Fatigue — 11-13%
• Pancreatitis risk — trials flagged severe abdominal pain for discontinuation and evaluation
• Gallbladder issues — rapid weight loss increases gallstone risk
• Thyroid C-cell tumors — same boxed warning as semaglutide (animal studies)

GI side effects were more intense than semaglutide in trial data due to the dual mechanism. Slower titration was associated with reduced severity.

mg to Units Conversion

On a standard 100-unit insulin syringe, each "unit" equals 0.01 mL (so 100 units = 1 mL). Once a research-grade compounded tirzepatide vial is reconstituted, the conversion from a target mg dose to syringe units depends entirely on the dilution. The two ratios most often described in community sources are below. Tirzepatide is the active ingredient in FDA-approved products for diabetes and chronic weight management; the FDA-approved formulations are pre-filled and require no syringe math. The conversions below apply to research-grade compounded forms only.

Reconstitution A: 10 mg vial + 2 mL BAC water (5 mg/mL) — the standard "20 units = 1 mg" dilution.

Reconstitution B: 10 mg vial + 1 mL BAC water (10 mg/mL) — half the volume per dose; better for higher-mg draws that would exceed one syringe at 5 mg/mL.

These conversions reflect the dilutions documented in published reconstitution protocols and community sources. They report how reconstitution math is described, not a recommended dosing schedule.

Frequently Asked Questions

Related Guides

• Tirzepatide Benefits — 8 research-backed effects beyond weight loss
• Where to Buy Tirzepatide — pricing, vial sizes, and COA verification
• Tirzepatide Results Timeline — Week-by-week expectations
• Tirzepatide Side Effects — 7 to watch for and how to minimize them
• Tirzepatide Bloodwork Guide — 7 labs to track
• Tirzepatide Reconstitution Guide — Mixing, dilution charts, and storage
• Tirzepatide Peptide Page — Vendor pricing and full profile
• Tirzepatide vs Semaglutide — Dual vs single agonist comparison
• AOD-9604 Benefits Guide — Research-backed effects of the GH fragment stacking partner
• Semaglutide Dosing Guide — Single GLP-1 agonist alternative
• Retatrutide Dosing Guide — Triple agonist next-generation peptide
• Calculate Your Tirzepatide Cycle Cost — Estimate vials needed and total cost

Related Reading

• How Much Bacteriostatic Water for Tirzepatide — community-cited reconstitution ratios + 28-day storage math on bacwatercatalog

References

For educational and research purposes only. This is not medical advice. Research peptides are not FDA-approved for human use.

Tabelas de referência

Perguntas frequentes

What tirzepatide doses do community sources report?

Community protocols self-report 0.5 mg subcutaneous 3 times per week (1.5 mg total weekly) in the morning on an empty stomach, cycled 8 weeks on / 8 weeks off. Reconstitution is typically described as a 10 mg vial with 2 mL bacteriostatic water — 0.5 mg works out to 10 units on an insulin syringe.

How do community protocols split tirzepatide across the week?

Community sources describe 0.5 mg every other day (Monday/Wednesday/Friday or Tuesday/Thursday/Saturday). Splitting the weekly dose is described as producing more stable levels and potentially fewer side effects than once-weekly dosing.

How long do community protocols run a tirzepatide cycle?

Most community protocols describe 8 weeks on, 8 weeks off, or continuing until a goal weight is reached. Cycling is described as a way to maintain receptor sensitivity.

What injection timing do community sources report for tirzepatide?

Most users self-report morning injection on an empty stomach, with 30-60 minutes before eating. The delayed gastric-emptying effect means food timing is described as mattering more with tirzepatide than with many other peptides.

How do trial and community protocols describe reconstituting tirzepatide?

Protocols describe adding 2 mL of bacteriostatic water to a 10 mg vial for a concentration of 5,000 mcg/mL. A 0.5 mg dose is 10 units on an insulin syringe. Storage is described as refrigerated, used within 28 days.

What stacking protocols are documented for tirzepatide?

Community sources commonly describe stacking with AOD-9604 for fat loss. Stacking with other GLP-1 agonists (semaglutide) is described as redundant due to overlapping mechanisms and increased side-effect risk. The dual GLP-1/GIP action is described as potent enough as monotherapy.